Greenrise Global: Year-end Letter to the Shareholders

BERLIN, Germany – December 22nd, 2021, Greenrise Global Brands Inc. (Frankfurt: C4T, ISIN: CA39540L1085) (CSE: XCX) (“Greenrise Global”) is pleased to provide a year-end letter to its shareholders. 

Dear Fellow Shareholders, 

Germany’s time has come.

The formation of the German government this month confirmed that recreational cannabis for adult use would become a reality in the near future, making Germany the first European Union country in the Group Seven (G7) to legalize medical, CBD and recreational use of cannabis fully.

Greenrise Global Brands is one of the few listed companies that is focused on cannabis in Germany. Our strategy is to be a leader in all legal parts of cannabis in Germany through our operating wholly-owned subsidiaries, Greenrise Life GmbH, Greenrise (Wellbeing) GmbH and AMP Alternative Medical Products GmbH.   

We formed Greenrise Life to lead our efforts in entering the recreational use market.  In the  upcoming year, Greenrise Life will be active in trying to support the policy as the German government enacts the required laws and policies.  AMP’s national sales team distributes medical cannabis products to clinics and pharmacies and may be important in distributing recreational cannabis to consumers if pharmacies are considered as a possible licensed dispensary. 

To further the discussion, Greenrise’s next episode in its Cannabis Round Table Series to be released in early 2022 will discuss the new government’s approach toward recreational cannabis with members of the coalition parties and moderated by Dr. Wieland Schinnenburg, MdB, a former spokesman for drug and addiction policy of the Free Democratic Party (FDP) and a well-respected medical cannabis expert.

During the year, Greenrise Wellbeing, our CBD cannabis and wellness subsidiary, launched Herbify, an oral cosmetic CBD brand sold online and Canavex® which is designed to be taken with medical cannabis prescriptions and sold through pharmacies and in drugstores next year.   Greenrise Wellbeing anticipates strong consumer demand for CBD wellness products in the coming years as there will be clarity on what products can be sold in Germany that meet the EU Novel Food authorization. 

Greenrise Wellbeing’s goal for the next year is to substantially grow sales through online and retail sales channels of its brands and strategically acquire CBD brands that are financially accretive and meet the Novel Food authorization requirements in Germany. 

Greenrise’s medical cannabis subsidiary, AMP, has built a strong reputation by supplying German patients with the highest quality medical cannabis products available. AMP’s strength is having front-line relationships with doctors and pharmacies, the only point-of-sale for medical cannabis to patients. 

AMP has built a national sales team specially trained to sell medical cannabis products, which generated approximately €500,000 in sales in its first year as an operating company selling Aphria and Bedrocan flowers as well as Aphria and Little Green Pharma extracts. AMP will be introducing its Dronabinol product to the market early next year in addition to other pharmaceutical products as the medical market moves away from flower. 

The pandemic has affected our sales team’s ability to meet with doctors whose time was either limited or restricted due to this special situation. Next year, AMP’s goal is to ensure it has enough supply of products and continue to train its sales team to meet the expected prescription demand when the pandemic either temporarily or finally resides. AMP continues to invest and advance its research into the efficacy and safety of medical cannabis with Waldhausklinik Deuringen gGmbH, a non-profit acute care clinic for internal medicine in the Free State of Bavaria, to help further education among doctors.

We would like to thank our shareholders for their continued support.  

Season’s Greetings to you and your family, and very best wishes for the New Year.

Yours sincerely,

Dr. Stefan Feuerstein                                         Hendrik Knopp
President and Director Director

About Greenrise Global Brands 

Greenrise Global helps people realize the beneficial properties of cannabis. Greenrise Global is a Canadian publicly traded corporation with two German operating subsidiaries: Greenrise GmbH (“Greenrise Wellbeing”) and AMP Alternative Medical Products GmbH (“AMP”). Greenrise Wellbeing is a CBD wellness firm based in Hamburg, with brands including Herbify and CANAVEX® in its portfolio. 

AMP is based in Erfurt and supplies medical cannabis products to pharmacies across Germany, including medical cannabis brands from Aphria, Bedrocan, Little Green Pharma and AMP’s branded line of products and sold through its nationwide sales team. AMP complies with the German Narcotic Drug Act (BtMG) and the Free State of Thuringia’s regulatory requirements, ensuring that products imported from around the world and sold in Germany meet the European Union’s Good Manufacturing Practice (EU-GMP) standard.

For more information about Greenrise Global, please visit

About Greenrise Cannabis Round Table Series

Episodes of the Round Table Series can be found at: (in German with English subtitles), Greenrise’s YouTube Channel and by all major podcast platforms (in German).




Hendrik Knopp,
+1 236-833-1602

Media Inquiries:

Valeria Bravo, Corporate and Media Communications    
+1 604-689-7533

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accept responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements that are based on the Company’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to its business plans and milestones and the timing thereof. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements do not guarantee future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.

SOURCE Greenrise Global Brands Inc.